UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 79

Sortiert nach

The association of BRCA1 and BRCA2 mutations with prostate cancer risk, frequency, and mortality: A meta‐analysis

The Prostate, 2019-06, Vol.79 (8), p.880-895

2019

Volltextzugriff (PDF)

Economic Evaluation of Talimogene Laherparepvec Plus Ipilimumab Combination Therapy vs Ipilimumab Monotherapy in Patients With Advanced Unresectable Melanoma

JAMA dermatology (Chicago, Ill.), 2019-01, Vol.155 (1), p.22

2019

Volltextzugriff (PDF)

Pembrolizumab Achieves a Complete Response in an NF-1 Mutated, PD-L1 Positive Malignant Peripheral Nerve Sheath Tumor: A Case Report and Review of the Benchmarks

Journal of immunotherapy (1997), 2022-05, Vol.45 (4), p.222

2022

Volltextzugriff (PDF)

Evaluation of Potential Drug‐Drug Interaction Risk of Pexidartinib With Substrates of Cytochrome P450 and P‐Glycoprotein

Journal of clinical pharmacology, 2021-03, Vol.61 (3), p.298-306

2021

Volltextzugriff (PDF)

A pilot study of Pan-FGFR inhibitor ponatinib in patients with FGFR-altered advanced cholangiocarcinoma

Investigational new drugs, 2022-02, Vol.40 (1), p.134-141

2022

Volltextzugriff (PDF)

A multicenter phase 1/2 study investigating the safety, pharmacokinetics, pharmacodynamics and efficacy of a small molecule antimetabolite, RX-3117, plus nab-paclitaxel in pancreatic adenocarcinoma

Investigational new drugs, 2022-02, Vol.40 (1), p.81-90

2022

Volltextzugriff (PDF)

E6201, an intravenous MEK1 inhibitor, achieves an exceptional response in BRAF V600E-mutated metastatic malignant melanoma with brain metastases

Investigational new drugs, 2019-08, Vol.37 (4), p.636-645

2019

Volltextzugriff (PDF)

Exploring the role of oncolytic viruses in hepatobiliary cancers

Immunotherapy, 2018-08, Vol.10 (11), p.971-986

2018

Volltextzugriff (PDF)

Using Advanced Molecular Profiling to Identify the Origin of and Tailor Treatment for an Intracranial Mass of Unknown Primary

JCO precision oncology, 2021-06, Vol.5, p.981

2021

Volltextzugriff (PDF)

Locally Advanced Rectal Cancer Evaluation by Magnetic Resonance Imaging after Neoadjuvant Therapy on Decision Making: Cancer Center Experience and Literature Review

Journal of gastrointestinal cancer, 2020-03, Vol.51 (1), p.254-259

2020

Volltextzugriff (PDF)

Hypoxia-activated prodrugs in the treatment of advanced pancreatic adenocarcinoma

Anti-cancer drugs, 2017-02, Vol.28 (2), p.127-132

2017

Volltextzugriff (PDF)

Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer

The New England journal of medicine, 2021-09, Vol.385 (12), p.1091-1103

2021

Volltextzugriff (PDF)

Phase 3 PANOVA-3 study: Tumor treating fields (TTFields) therapy concomitant with gemcitabine and nab-paclitaxel (GnP) for front-line treatment of locally advanced pancreatic cancer

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.TPS4199-TPS4199

2023

Volltextzugriff (PDF)

52683 Expert Guidance on the Prevention and Management of Dermatologic Adverse Events with Tumor Treating Fields Therapy in the Abdominal-Pelvic Region

Journal of the American Academy of Dermatology, 2024-09, Vol.91 (3), p.AB212-AB212

2024

Volltextzugriff (PDF)

Evaluation of emergency department (ED) visits by oncology patients: A running comparison to admissions and ED visits under the CMS OP-35 ruling

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.e18683-e18683

2021

Volltextzugriff (PDF)

A retrospective real-world major bleeding (MB) comparison of direct oral anticoagulants (DOAC) and low molecular weight heparin (LMWH) in genitourinary cancer-associated venous thromboembolism (GU-CAVTE) with reported randomized clinical trials (RTC)

Journal of clinical oncology, 2021-02, Vol.39 (6_suppl), p.410-410

2021

Volltextzugriff (PDF)

Clinical outcomes of immune checkpoint inhibitor treatment in patients with classic cold tumors identified to have a high tumor mutational burden via ctDNA

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.2561-2561

2023

Volltextzugriff (PDF)

Novel approaches in marginal zone lymphoma: Systematic review

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.e20089-e20089

2020

Volltextzugriff (PDF)

Analysis of pancreatobiliary adenocarcinoma (PBC) treatment response and resistance utilizing circulating tumor DNA (ctDNA)

Journal of clinical oncology, 2020-02, Vol.38 (4_suppl), p.758-758

2020

Volltextzugriff (PDF)

Transitioning ifosfamide based chemotherapy to the outpatient setting: A model of implementation of transitioning chemotherapy outpatient in a safety net hospital

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.1540-1540

2021

Volltextzugriff (PDF)

Responses to immune checkpoint inhibition among MSI-H pancreatic ductal adenocarcinoma: A multi-institutional case series

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.4145-4145

2022

Volltextzugriff (PDF)

Phase I study of HFB200301, a first-in-class TNFR2 agonist monoclonal antibody in patients with solid tumors selected via Drug Intelligent Science (DIS)

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS2670-TPS2670

2022

Volltextzugriff (PDF)

ACCRU-GI-2008: A phase II randomized study of atezolizumab (Atezo) plus a multi-kinase inhibitor (MKI) versus MKI alone in patients with unresectable advanced hepatocellular carcinoma (aHCC) who previously received atezolizumab plus bevacizumab (Bev)

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS4170-TPS4170

2022

Volltextzugriff (PDF)

KRAS wild-type pancreatic ductal adenocarcinoma: Molecular and therapeutic opportunities

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.4130-4130

2022

Volltextzugriff (PDF)

1 – 25 von 79

Suche als RSS-Feed

Aktive Filter

KollektionBMJ

KollektionJournals@Ovid Full Text

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(79)
Mit Volltextzugriff
(71)

Publikationsform

Artikel
(78)
Tagungsberichte
(1)

Sprache

Englisch
(79)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

The association of BRCA1 and BRCA2 mutations with prostate cancer risk, frequency, and mortality: A meta‐analysis

Economic Evaluation of Talimogene Laherparepvec Plus Ipilimumab Combination Therapy vs Ipilimumab Monotherapy in Patients With Advanced Unresectable Melanoma

Pembrolizumab Achieves a Complete Response in an NF-1 Mutated, PD-L1 Positive Malignant Peripheral Nerve Sheath Tumor: A Case Report and Review of the Benchmarks

Evaluation of Potential Drug‐Drug Interaction Risk of Pexidartinib With Substrates of Cytochrome P450 and P‐Glycoprotein

A pilot study of Pan-FGFR inhibitor ponatinib in patients with FGFR-altered advanced cholangiocarcinoma

A multicenter phase 1/2 study investigating the safety, pharmacokinetics, pharmacodynamics and efficacy of a small molecule antimetabolite, RX-3117, plus nab-paclitaxel in pancreatic adenocarcinoma

E6201, an intravenous MEK1 inhibitor, achieves an exceptional response in BRAF V600E-mutated metastatic malignant melanoma with brain metastases

Exploring the role of oncolytic viruses in hepatobiliary cancers

Using Advanced Molecular Profiling to Identify the Origin of and Tailor Treatment for an Intracranial Mass of Unknown Primary

Locally Advanced Rectal Cancer Evaluation by Magnetic Resonance Imaging after Neoadjuvant Therapy on Decision Making: Cancer Center Experience and Literature Review

Hypoxia-activated prodrugs in the treatment of advanced pancreatic adenocarcinoma

Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer

PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma

Phase 3 PANOVA-3 study: Tumor treating fields (TTFields) therapy concomitant with gemcitabine and nab-paclitaxel (GnP) for front-line treatment of locally advanced pancreatic cancer

52683 Expert Guidance on the Prevention and Management of Dermatologic Adverse Events with Tumor Treating Fields Therapy in the Abdominal-Pelvic Region

Evaluation of emergency department (ED) visits by oncology patients: A running comparison to admissions and ED visits under the CMS OP-35 ruling

A retrospective real-world major bleeding (MB) comparison of direct oral anticoagulants (DOAC) and low molecular weight heparin (LMWH) in genitourinary cancer-associated venous thromboembolism (GU-CAVTE) with reported randomized clinical trials (RTC)

Clinical outcomes of immune checkpoint inhibitor treatment in patients with classic cold tumors identified to have a high tumor mutational burden via ctDNA

Novel approaches in marginal zone lymphoma: Systematic review

Analysis of pancreatobiliary adenocarcinoma (PBC) treatment response and resistance utilizing circulating tumor DNA (ctDNA)

Transitioning ifosfamide based chemotherapy to the outpatient setting: A model of implementation of transitioning chemotherapy outpatient in a safety net hospital

Responses to immune checkpoint inhibition among MSI-H pancreatic ductal adenocarcinoma: A multi-institutional case series

Phase I study of HFB200301, a first-in-class TNFR2 agonist monoclonal antibody in patients with solid tumors selected via Drug Intelligent Science (DIS)

ACCRU-GI-2008: A phase II randomized study of atezolizumab (Atezo) plus a multi-kinase inhibitor (MKI) versus MKI alone in patients with unresectable advanced hepatocellular carcinoma (aHCC) who previously received atezolizumab plus bevacizumab (Bev)

KRAS wild-type pancreatic ductal adenocarcinoma: Molecular and therapeutic opportunities

Aktive Filter

Suchergebnisse filtern